KALV — KalVista Pharmaceuticals, Inc.

Summary of KalVista Pharmaceuticals Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: KalVista reported $1.4 million in net revenue for the launch period of EKTERLY, primarily from stocking orders by specialty pharmacies.
• Operating Expenses: Total operating expenses were $60.4 million, with approximately $15 million in R&D and $45 million in SG&A, reflecting increased spending related to the EKTERLY launch.
• Cash Position: The company had approximately $191 million in cash and investments as of July 31, 2025, expected to fund operations into 2027.

2. Strategic Updates and Business Highlights

• FDA Approval: EKTERLY received FDA approval as the first oral on-demand therapy for acute HAE attacks, with a U.S. launch initiated immediately.
• Market Response: Initial uptake exceeded expectations, with nearly 5% of the U.S. HAE population submitting prescriptions within weeks of launch.
• International Expansion: Regulatory progress includes a positive CHMP opinion in Europe, marketing authorization in the U.K., and anticipated approval in Japan by year-end 2025.
• Commercial Infrastructure: Investments in commercial infrastructure prior to approval are yielding positive results, with strong engagement from patients, physicians, and payers.

3. Forward Guidance and Outlook

• Launch Progress: The company expects continued growth in prescription volume and patient engagement as the launch progresses. Future quarters will see evolving key performance indicators (KPIs) as they track repeat prescriptions and utilization rates.
• Market Growth: KalVista has revised its market growth expectations upward by 25%, reflecting updated pricing and market dynamics.

4. Bad News, Challenges, or Points of Concern

• Insurance Coverage: Some payers may require step-through protocols involving generic therapies, which could complicate access for some patients. However, the majority of patients have prior experience with generic icatibant, easing the transition.
• Initial Patient Access: While initial demand is strong, the company acknowledges that formal coverage policies typically take up to six months to establish, which may impact revenue recognition in the short term.
• Adverse Events: Although no significant side effects have been reported, the company remains vigilant during the initial launch phase, where adverse events are typically most reported.

5. Notable Q&A Insights

• Quickstart Program: The Quickstart program allows immediate access to EKTERLY at no charge while pursuing medical exceptions for paid access. Initial feedback indicates a smooth process, with some patients already receiving paid shipments.
• Patient Demographics: The early adopters of EKTERLY include a broad range of patients, particularly those with a high burden of disease, indicating strong market interest beyond just previous users of other therapies.
• Future Reporting: The company plans to share more detailed KPIs in future calls, including percentage lives covered and detailed prescription patterns as they gather more data post-launch.

Overall, KalVista Pharmaceuticals is experiencing a strong launch of EKTERLY, with positive initial metrics and strategic plans for expansion, though challenges related to insurance coverage and patient access remain.